The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Disclosed herein are techniques related to event-oriented predictions of glycemic responses. In some embodiments, the techniques may involve accessing a prediction model that correlates a person's glycemic responses to events and the person's physiological parameters during the events. The techniques may also involve obtaining a glucose level measurement of the person during an event. Additionally, the techniques may involve determining, based on the glucose level measurement, a physiological parameter of the person during the event. Furthermore, the techniques may involve predicting the person's glycemic response to the event based on applying the prediction model to the physiological parameter.

Disclosed herein are techniques related to event-oriented predictions of glycemic responses. In some embodiments, the techniques may involve accessing a prediction model that correlates a person's glycemic responses to events and the person's physiological parameters during the events. The techniques may also involve obtaining a glucose level measurement of the person during an event. Additionally, the techniques may involve determining, based on the glucose level measurement, a physiological parameter of the person during the event. Furthermore, the techniques may involve predicting the person's glycemic response to the event based on applying the prediction model to the physiological parameter.

The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.

The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.

The present invention aims to provide a preparation containing a compound of the formula [I] or a pharmaceutically acceptable salt thereof or a hydrate thereof having improved pharmacokinetics, and a manufacturing method thereof. The present invention relates to a solid dispersion containing (1) an amorphous compound represented by the following formula [I]:

##STR00001##

or a pharmaceutically acceptable salt thereof or a hydrate thereof, and

(2) one to four kinds of pharmaceutically acceptable polymers selected from the group consisting of hydroxypropylmethylcellulose acetate succinate, methylcellulose, hypromellose and polyvinyl alcohol, and a manufacturing method thereof.

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

Modified G6PC (glucose-6-phosphatase, catalytic subunit) nucleic acids and glucose-6-phosphatase-α (G6Pase-α) enzymes with increased phosphohydrolase activity are described. Also described are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing modified G6Pase-α. The disclosed AAV vectors and rAAV can be used for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia), and complications thereof.

The present invention relates to treatments of diabetic macular edema (DME) and impaired visual acuity, comprising intravitreally administering the compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof): Formula (A).

##STR00001##

The present invention relates to treatments of diabetic macular edema (DME) and impaired visual acuity, comprising intravitreally administering the compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof): Formula (A).

##STR00001##